Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community.

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

A local cancer survivor, Robert Dames, has released a new book titled "Cancer - What Now" to assist others in navigating the ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

Multiple myeloma is most common in people age 65 and older. The average age of diagnosis is 70, with fewer than 1% of cases diagnosed in people younger than 35.